Answers are grounded in this paper and cite their sources.
The editorial emphasizes the importance of comprehensive phenotyping of endomyocardial biopsies, including pro- and anti-inflammatory markers, to improve risk stratification and targeted therapies in dilated cardiomyopathy.
This article refers to ‘Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy,’ by T. Nakayama et al., published in this issue on pages 490–498. Dilated cardiomyopathy (DCM) is defined as a cardiac disorder characterized by LV or biventricular systolic dysfunction and dilatation that are not explained by abnormal loading conditions or CAD. Inflammatory cardiomyopathy (CMi), an inflammatory disease of the myocardium, associated with necrosis and/or degeneration of cardiomyocytes, is the primordial aetiology underlying DCM.1 Myocardial inflammation is reflected by infiltration of lymphocytes and macrophages, and increased expression of cell adhesion molecules.2 Accumulating evidence confirms the relevance of inflammation in the pathogenesis of DCM and heart failure.3 Furthermore, an increased cardiac immune cell infiltration evidenced by immunohistochemistry, but not by the Dallas criteria, which are based on a histopathological evaluation, predicts the poor outcome in CMi patients.2 The relevance of intramyocardial inflammation as an adverse prognostic factor in CMi is further supported and specified by Escher et al.4 who screened for the cytotoxic cell marker perforin, a molecule released by T cells and natural killer cells in endomyocardial biopsies (EMBs), and found that detection of perforin in the myocardium is a key predictor of LVEF course in suspected CMi.4 In this issue of the journal, Nakayama et al.5 illustrated the clinical impact of macrophage infiltrates in EMBs of DCM patients. In particular, in addition to CD3 T lymphocytes, they screened for the presence of CD68 macrophages, reflecting whole macrophages, and of CD163-positive cells, representing M2 macrophages, known to have anti-inflammatory and profibrotic properties in contrast to the ‘classical’ proinflammatory M1 macrophages. They demonstrated that higher counts of cardiac-infiltrating CD3 T lymphocytes, CD68 macrophages, and CD163-positive cells in EMBs of DCM patients corresponded to a poorer outcome. Multivariate regression analysis further indicated that the number of myocardial-positive CD163 infiltrates was an independent determinant of collagen area fraction among the variables that influence the disease course of DCM. The positive correlation between M2 macrophage infiltration and collagen formation suggests that a phenotypic polarization of macrophages towards M2 may crucially contribute to the fibrotic ventricular remodelling in the disease process of DCM. This study illustrating that both pro-and anti-inflammatory infiltrates were associated with a poor prognosis in DCM patients indicates the complex immune status and its diversity during the disease progression. At present, to the best of our knowledge, this study is unique in its kind since it examined pro- as well as anti-inflammatory markers in EMBs of DCM patients. So far, a plethora of biomarkers predicting the outcome of CMi have already been defined, ranging from adiponectin, over microRNA, to fibrotic markers. Many studies will also follow demonstrating that a cell X or a factor Y is indicative for a poor prognosis in DCM. However, the question arises as to what information do all these individual markers bring us in terms of clinical translation, returning us to the crucial question of which information of clinical relevance do we actually need. Basically, we need to understand and characterize in detail the onset of DCM via markers and find specific therapeutic targets. At present, patients who suffer from DCM have only a 5-year survival rate of 55% under current heart failure treatment,6 indicating the need for target-specific strategies. Furthermore, no diagnostic and prognostic strategies are available for distinct virus-negative myocarditis patients who recover vs. those patients in which the disease progresses further to inflammatory dilated cardiomyopathy (DCMi) due to an uncontrolled cardiac inflammatory reaction.2 Due to the lack of identification of these patients at risk, specific immunosuppressive interventions are often started too late. Thus, myocarditis includes heterogeneous forms, which need to be better characterized in view of better target-specific therapies. Identification of such patients at risk is of translational relevance since (i) those patients could benefit from an earlier initiated intervention (implantation of devices, starting standard immunosuppressive strategies); (ii) the risk (immune) profile would allow generation of the hypothesis if, for example, an impaired regulatory T cell (Tregs) system could serve as a therapeutic target. This is important since Tregs can be pharmacologically stimulated by interleukin-2 agonists,7 whose therapeutic efficacy has already been shown in different disorders. A dysregulated immune system, such as an impaired Tregs system, an imbalance in pro- vs. anti-inflammatory monocytes, or in M1 to M2 macrophages, may contribute to this imbalanced proinflammatory reaction. As such, M1 macrophages should be screened in relation to M2 macrophages, proinflammatory monocytes to anti-inflammatory monocytes, and Tregs to T effector cells, to assess the resultant mixed phenotype. Unfortunately, the present study only screened for M2 and not for M1 macrophages, whereas it also quantified total CD68 macrophages. The assessment of the ratio of M2 to CD68 would have been of added value. Moreover, it should be recognized, as also pointed out by the authors as a limitation of the study, that CD163 is only one of the markers of M2 macrophages. Phenotypic distinction between the polarized M1 and M2 macrophages involves differential expression of cell surface receptors. Among these, CD86, major histocompatibility complex-II, and the macrophage receptor with collagenous structure are typically associated with M1 activation, whereas the mannose receptor, dectin-1, and CD163 fit an M2 signature. Consequently, complete identification of M1 vs. M2 polarization requires analyses of additional markers, which can be assessed via immunohistochemistry. With respect to Tregs, those cells can be analysed in EMBs via an epigenetic approach based on the quantitative analysis of DNA demethylation within the FoxP3 locus, allowing differentiation between activated T cells and Tregs,8 which is not possible via sole screening of FoxP3 expression. Such an epigenetic approach further enables the identification of T effector cells, allowing screening for Tregs to T effector cells in EMBs. The assessment of pro- and anti-inflammatory monocyte subsets requires a flow cytometry approach, needed to quantify CD14CD16-expressing subsets. As demonstrated for the analysis of monocyte subsets in murine cardiac hearts, flow cytometry is sensitive enough to screen the limited amount of cardiac mononuclear cells in EMBs, which is not the case for multidimensional mass cytometry, requiring a higher threshold of screened cells.9 Imaging mass spectrometry on EMBs, allowing regional-specific evaluation of protein musters,10 further enables characterization and differentiation of the heterogenous forms of CMi as well as other forms of heart failure. Based on imaging mass spectrometry, clustering of patients could be carried out, discriminating patients with or without cardiac inflammation (Figure 1). This profound characterization of EMBs via phenomics (proteomics, immune cell profiling, etc.) together with clinical patient characterization (ECG, echo, lab and physical tests, etc.), so-called phenomapping,11 will further allow improved classification of heterogeneous clinical syndromes, such as CMi, with the ultimate goal of defining therapeutically homogeneous patient subclasses. (Immuno)histological analysis and screening for cardiotropic viruses of EMBs is, to date, the gold standard to diagnose CMi12, 13 despite hurdles including sampling error problems due to small sample size and the invasiveness of the method. It should be addressed that a major limitation of the present study is the absence of screening for cardiotropic viruses, which are the most common cause of myocarditis and DCM, and influence the prognosis as well as the therapeutic regime. With respect to alternatives to EMBs, it should be noted that so far, non-invasive magnetic resonance imaging cannot replace EMBs for the diagnosis of myocarditis due to the still high negative predictive value in acute as well as chronic settings.14 To overcome the sampling error problem of small biopsies, liquid biopsies in the form of transcoronary gradients, previously shown to describe the cardiac passage of cells and thus the resulting engraftment of these specific cells in the heart,15 may form an alternative strategy, which merits further investigation. The search for non-invasive specific blood tests also allowing repeated longitudinal monitoring of the status of the disease is also still warranted. We thank Oliver Klein of the BCRT Cardioproteomics lab for the imaging mass spectrometry data. This study is supported by the BMBF and Land Berlin (Identification of new biomarkers by inflammatory cardiomyopathy) to C.T., and by the DZHK to S.V.L. and C.T. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Linthout et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: